Tam Derrick Y, Rahouma Mohamed, An Kevin R, Gaudino Mario F L, Karkhanis Reena, Fremes Stephen E
Division of Cardiac Surgery, Schulich Heart Centre, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
Department of Cardiothoracic Surgery, Weill Cornell Medical College, New York, New York.
J Card Surg. 2019 Apr;34(4):196-201. doi: 10.1111/jocs.14010. Epub 2019 Mar 9.
The incidence of severe coronary artery disease (CAD) in patients with end-stage renal disease (ESRD) on dialysis is high. Coronary artery bypass grafting (CABG) is the preferred treatment in those with severe CAD. Bilateral internal thoracic artery (BITA) vs single internal thoracic artery (SITA) grafting has been shown to improve late survival in other high-risk populations. In ESRD, comparative studies are limited by sample size to detect outcome differences. We sought to determine the late survival and early outcomes of BITA compared with SITA in patients with ESRD.
MEDLINE and EMBASE were searched from inception to 2017 for studies directly comparing BITA to SITA in patients with ESRD undergoing CABG. The primary outcome was late survival; secondary outcomes were in-hospital/30-day mortality, stroke, and deep sternal wound infection (DSWI). Kaplan-Meier curve reconstruction for late mortality was performed.
Five studies (three adjusted [n = 197] and two unadjusted observational studies [n = 231]) were included in the analysis. Reported ITA skeletonization ranged from 83% to 100% (median: 100%). There was no difference in in-hospital mortality (risk risk [RR], 0.84; 95% confidence interval [95%CI], 0.36,1.98; P = 0.70), perioperative stroke (RR, 1.97; 95%CI, 0.58,6.66; P = 0.28), and DSWI (RR, 1.56; 95%CI, 0.60,4.07; P = 0.36) between BITA and SITA. All studies reported adjusted late mortality, which was similar between BITA and SITA (incident rate ratio, 0.81; 95%CI, 0.59,1.11) at mean 3.7-year follow-up.
BITA grafting is safe in patients with ESRD although there was no survival benefit at 3.7 years. Additional studies with longer follow-up are required to determine the potential late benefits of BITA grafting in patients with ESRD.
接受透析治疗的终末期肾病(ESRD)患者中,严重冠状动脉疾病(CAD)的发病率较高。冠状动脉旁路移植术(CABG)是重度CAD患者的首选治疗方法。在其他高危人群中,双侧胸廓内动脉(BITA)移植与单支胸廓内动脉(SITA)移植相比,已显示可改善远期生存率。在ESRD患者中,比较性研究因样本量限制而难以检测出结局差异。我们旨在确定ESRD患者中BITA与SITA相比的远期生存率和早期结局。
检索MEDLINE和EMBASE数据库,从建库至2017年,查找直接比较ESRD患者接受CABG时BITA与SITA的研究。主要结局为远期生存率;次要结局为住院/30天死亡率、卒中及深部胸骨伤口感染(DSWI)。对晚期死亡率进行Kaplan-Meier曲线重建。
分析纳入5项研究(3项校正研究[n = 197]和2项未校正观察性研究[n = 231])。报道的胸廓内动脉骨骼化率为83%至100%(中位数:100%)。BITA与SITA之间在住院死亡率(风险比[RR],0.84;95%置信区间[95%CI],0.36,1.98;P = 0.70)、围手术期卒中(RR,1.97;95%CI,0.58,6.66;P = 0.28)及DSWI(RR,1.56;95%CI,0.60,4.07;P = 0.36)方面无差异。所有研究均报道了校正后的晚期死亡率,在平均3.7年的随访中,BITA与SITA之间相似(发病率比,0.81;95%CI,0.59,1.11)。
BITA移植对ESRD患者是安全的,尽管在3.7年时未观察到生存获益。需要进行更长时间随访的进一步研究,以确定BITA移植对ESRD患者的潜在远期益处。